Cargando…

A Novel Predictor of Pathologic Complete Response for Neoadjuvant Immunochemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

PURPOSE: Neoadjuvant immunochemotherapy (nICT) for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC) has attracted widespread attention recently, whose safety and clinical benefit was observed in clinical researches. This study aimed to develop and validate a novel predictor s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Yalan, Xin, Dao, Wang, Huike, Guan, Lulu, Meng, Xiangrui, Lu, Taiying, Bai, Xiwen, Wang, Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083012/ https://www.ncbi.nlm.nih.gov/pubmed/37042015 http://dx.doi.org/10.2147/JIR.S395231

Ejemplares similares

Pathological Responses of the Primary Tumor and Locoregional Lymph Nodes After Neoadjuvant Immunochemotherapy in Esophageal Squamous Cell Cancer
por: Huang, Shu Jie, et al.
Publicado: (2022)

Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Xu, Lei, et al.
Publicado: (2022)

(18)F‐FDG PET/CT predicts the role of neoadjuvant immunochemotherapy in the pathological response of esophageal squamous cell carcinoma
por: Wang, Shuohua, et al.
Publicado: (2023)

Prediction of pathologic complete response prediction in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy: A real-world study
por: Feng, Jifeng, et al.
Publicado: (2023)

Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma
por: Huang, Ren-Wen, et al.
Publicado: (2014)

Predictive value of systemic immune-inflammation index for pathological complete response in patients receiving neoadjuvant immunochemotherapy for locally advanced esophageal cancer
por: Han, Wu, et al.
Publicado: (2023)

Delta-radiomics based on CT predicts pathologic complete response in ESCC treated with neoadjuvant immunochemotherapy and surgery
por: Li, Kaiyuan, et al.
Publicado: (2023)

Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?
por: Hong, Zhi-Nuan, et al.
Publicado: (2022)

Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa
por: Gao, Lei, et al.
Publicado: (2022)

Reactivation of mutant p53 in esophageal squamous cell carcinoma by isothiocyanate inhibits tumor growth
por: Guan, Lulu, et al.
Publicado: (2023)

A novel immune-nutritional score predicts response to neoadjuvant immunochemotherapy after minimally invasive esophagectomy for esophageal squamous cell carcinoma
por: Feng, Jifeng, et al.
Publicado: (2023)

Enhancing Prediction for Tumor Pathologic Response to Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Cancer by Dynamic Parameters from Clinical Assessments
por: Song, Xin-Yun, et al.
Publicado: (2023)

Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial)
por: Huang, Yingying, et al.
Publicado: (2023)

Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2023)

Neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: the more cycles, the better?
por: Ulas, Ezgi B., et al.
Publicado: (2023)

The usefulness of pretreatment controlling nutritional status score for predicting recurrence in patients with esophageal squamous cell carcinoma undergoing neoadjuvant immunochemotherapy: A real-world study
por: Feng, Jifeng, et al.
Publicado: (2022)

The prognostic significance of the circumferential resection margin in esophageal squamous cell carcinoma patients without neoadjuvant treatment
por: Yang, Zhaoyang, et al.
Publicado: (2022)

Impact of the interval between neoadjuvant immunochemotherapy and surgery on surgical–pathological outcomes in non-small cell lung cancer
por: Chen, Jiawei, et al.
Publicado: (2022)

Are more courses of immunochemotherapy beneficial for the short‐term outcome of locally advanced esophageal squamous cell carcinoma?
por: Huang, Yuanheng, et al.
Publicado: (2023)

Impact of complete surgical resection on outcome in aggressive non‐Hodgkin lymphoma treated with immunochemotherapy
por: Schmitz, Christine, et al.
Publicado: (2020)

Lymphocyte-monocyte ratio as a predictive marker for pathological complete response to neoadjuvant therapy in esophageal squamous cell carcinoma
por: Zhao, Kewei, et al.
Publicado: (2020)

Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010)
por: Shen, Jianfei, et al.
Publicado: (2021)

CT-based radiomic signatures for prediction of pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy
por: Yang, Zhining, et al.
Publicado: (2019)

Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer
por: Liu, Chaoyuan, et al.
Publicado: (2023)

Tumor microenvironment features decipher the outperformance of neoadjuvant immunochemotherapy over chemotherapy in resectable non-small cell lung cancer
por: Cai, Wenhan, et al.
Publicado: (2022)

Neoadjuvant immunotherapy for resectable esophagal squamous cell carcinoma: An ace up the sleeve
por: Zhou, Qing, et al.
Publicado: (2023)

Applying post-neoadjuvant pathologic stage as prognostic tool in esophageal squamous cell carcinoma
por: Han, Weiming, et al.
Publicado: (2022)

Pathologic Complete Response Prediction to Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Real-World Evidence from Integrative Inflammatory and Nutritional Scores
por: Feng, Jifeng, et al.
Publicado: (2022)

NEOADJUVANT CHEMORADIOTHERAPY FOLLOWED BY TRANSHITAL ESOPHAGECTOMY IN LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: IMPACT OF PATHOLOGICAL COMPLETE RESPONSE
por: ALVES, Iuri Pedreira Fillardi, et al.
Publicado: (2021)

Is adjuvant immunotherapy a new standard for non‐pathological complete response patients with resectable esophageal squamous cell carcinoma?
por: Wang, Jun, et al.
Publicado: (2022)

An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma
por: Zhang, Chaoqi, et al.
Publicado: (2020)

Pulmonary Resection after Radiosurgery and Neoadjuvant Immunochemotherapy for NSCLC Patients with Synchronous Brain Metastasis—A Case Series of Three Patients
por: Koch, Agnes, et al.
Publicado: (2022)

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
por: Yang, Weixiong, et al.
Publicado: (2022)

The role of miR-145-5p in esophageal squamous cell carcinoma tumor-associated macrophages and selection of immunochemotherapy
por: Lin, Junhong, et al.
Publicado: (2022)

Metformin Downregulates PD-L1 Expression in Esophageal Squamous Cell Carcinoma by Inhibiting IL-6 Signaling Pathway
por: Lu, Yao, et al.
Publicado: (2021)

Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
por: He, Wenwu, et al.
Publicado: (2022)

Comprehensive (18)F-FDG PET-based radiomics in elevating the pathological response to neoadjuvant immunochemotherapy for resectable stage III non-small-cell lung cancer: A pilot study
por: Cui, Yingpu, et al.
Publicado: (2022)

“Major pathologic response” in lymph nodes: a modified nodal classification for non-small cell lung cancer patients treated with neoadjuvant immunochemotherapy
por: Deng, Hongsheng, et al.
Publicado: (2023)

Effect of circumferential resection margin status on survival and recurrence in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy
por: Gu, Yi-Min, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c69olobppj1fskamu8oc1jdpur